Research Paper Volume 13, Issue 11 pp 15164—15192

Identification and validation of a novel eight mutant-derived long non-coding RNAs signature as a prognostic biomarker for genome instability in low-grade glioma

Validation of the lncRNA signature for genomic instability used to predict outcomes in the testing and TCGA set. (A) Validation of overall survival in low- or high-risk patients predicted by pooling GILncSig with Kaplan-Meier estimates. (B) Time-dependent ROC curves of GILncSig at 1, 2 and 3 years in the testing group. (C) Verification of LncRNA expression patterns, the profile of somatic mutations and UBQLN4 expression in patients in low- and high-risk groups. (D–E) Box plots for the distribution of somatic mutations and UBQLN4 expression in high- and low-risk groups of patients. (F–J) Verification of the above results using the TCGA set.

Figure 4. Validation of the lncRNA signature for genomic instability used to predict outcomes in the testing and TCGA set. (A) Validation of overall survival in low- or high-risk patients predicted by pooling GILncSig with Kaplan-Meier estimates. (B) Time-dependent ROC curves of GILncSig at 1, 2 and 3 years in the testing group. (C) Verification of LncRNA expression patterns, the profile of somatic mutations and UBQLN4 expression in patients in low- and high-risk groups. (DE) Box plots for the distribution of somatic mutations and UBQLN4 expression in high- and low-risk groups of patients. (FJ) Verification of the above results using the TCGA set.